These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 15051759)

  • 1. Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D.
    Eleme K; Taner SB; Onfelt B; Collinson LM; McCann FE; Chalupny NJ; Cosman D; Hopkins C; Magee AI; Davis DM
    J Exp Med; 2004 Apr; 199(7):1005-10. PubMed ID: 15051759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
    Song H; Kim J; Cosman D; Choi I
    Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
    Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
    Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
    Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
    Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
    Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
    Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
    Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
    Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein.
    Welte SA; Sinzger C; Lutz SZ; Singh-Jasuja H; Sampaio KL; Eknigk U; Rammensee HG; Steinle A
    Eur J Immunol; 2003 Jan; 33(1):194-203. PubMed ID: 12594848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of natural killer (NK) cell cytotoxicity by fever-range thermal stress is dependent on NKG2D function and is associated with plasma membrane NKG2D clustering and increased expression of MICA on target cells.
    Ostberg JR; Dayanc BE; Yuan M; Oflazoglu E; Repasky EA
    J Leukoc Biol; 2007 Nov; 82(5):1322-31. PubMed ID: 17711975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
    Waldhauer I; Steinle A
    Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
    Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C
    J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the NKG2D ligand UL16 binding protein-1 (ULBP-1) on dendritic cells.
    Schrama D; Terheyden P; Otto K; Kämmerer U; Bröcker EB; Lühder F; Cosman D; Andersen MH; Becker JC
    Eur J Immunol; 2006 Jan; 36(1):65-72. PubMed ID: 16342232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The inhibitory effects of synthetic short peptides, mimicking MICA and targeting at NKG2D receptors, on function of NK cells.
    Zhang B; Wei H; Zheng X; Zhang J; Sun R; Tian Z
    Peptides; 2005 Mar; 26(3):405-12. PubMed ID: 15652646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells.
    Sutherland CL; Chalupny NJ; Schooley K; VandenBos T; Kubin M; Cosman D
    J Immunol; 2002 Jan; 168(2):671-9. PubMed ID: 11777960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four novel ULBP splice variants are ligands for human NKG2D.
    Cao W; Xi X; Wang Z; Dong L; Hao Z; Cui L; Ma C; He W
    Int Immunol; 2008 Aug; 20(8):981-91. PubMed ID: 18544572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of NKG2D ligands on human dendritic cells by TLR ligand stimulation and RNA virus infection.
    Ebihara T; Masuda H; Akazawa T; Shingai M; Kikuta H; Ariga T; Matsumoto M; Seya T
    Int Immunol; 2007 Oct; 19(10):1145-55. PubMed ID: 17878262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UL16 binding proteins.
    Cao W; He W
    Immunobiology; 2004; 209(3):283-90. PubMed ID: 15518340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of NKG2D ligands in multidrug-resistant nasopharyngeal carcinoma cell line CNE2/DDP and their effects on cytotoxicity of natural killer cells].
    Mei JZ; Guo KY; Wei HM; Song CY
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):887-9. PubMed ID: 17584663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of NKG2D ligands on dendritic cells at different development stages and its effect on cytotoxicity of NK cells].
    Tu SF; Guo KY; Hu LS; Mei JZ; Zhou J; Sun M
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Apr; 24(4):341-3, 347. PubMed ID: 18394338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor.
    Cosman D; Müllberg J; Sutherland CL; Chin W; Armitage R; Fanslow W; Kubin M; Chalupny NJ
    Immunity; 2001 Feb; 14(2):123-33. PubMed ID: 11239445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
    Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
    Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.